HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Andrea Pascual-Oliver und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. Hauptthemen laut MEDLINE: HLA-DQ alpha-Chains. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
We lack predictors of response to biologics in the management of patients with inflammatory bowel disease (IBD). A recent study has shown a significant association between HLA-DQA1*05 carriers and the development of loss of response to anti-tumor necrosis factor (TNF) mediated by immunogenicity.
Methods
Retrospective single-center cohort study including IBD patients who had received anti-TNF therapy as a first biologic and whose HLA-DQA1*05 had been determined. Primary nonresponse and secondary failure (assessed by survival analysis) have been evaluated as well as safety outcomes.
Results
A total of 199 IBD patients (161 [81%] with Crohn’s disease and 38 [19%] with ulcerative colitis) were included. A total of 42.4% were HLA-DQA1*05 carriers and 60% received combination therapy at the start of anti-TNF treatment. Median follow-up was 24 (interquartile range, 11-66) months. No statistically significant differences were found in primary nonresponse to anti-TNF (89.3% vs 87.8%; P = .825), depending on HLA carriers and noncarriers. No differences in secondary loss of response according to HLA variant in any of the analyses performed (full cohort, according to IBD or anti-TNF type) were observed. Again, no differences were observed in patients treated with combination therapy. In terms of safety, no significant differences were found in the rate of infusion reactions or serious adverse events.
Conclusion
In our real-life cohort of IBD patients treated for the first time with anti-TNF, being an HLA-DQA1*05 carrier did not act as a predictor of response failure, either primary or secondary. The safety of anti-TNF treatment has also not been influenced by the variant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain.
- Gastroenterology Department, Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain.
- Pharmacy Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- Biochemistry and Genetics Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
ORCID-Profile: Andrea Pascual-Oliver, Diego Casas-Deza
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Pascual-Oliver, A., Casas-Deza, D., Cuarán, C., García-López, S., Corsino-Roche, P., Sierra-Moros, E., Olier-Martínez, P., González-Tarancón, R., & Vicente-Lidón, R. (2024). HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad130
Vancouver
Pascual-Oliver A, Casas-Deza D, Cuarán C, García-López S, Corsino-Roche P, Sierra-Moros E, et al. HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad130
BibTeX
@article{PascualOliver2024,
author = {Pascual-Oliver, Andrea and Casas-Deza, Diego and Cuarán, Camila and García-López, Santiago and Corsino-Roche, Pilar and Sierra-Moros, Eva and Olier-Martínez, Pilar and González-Tarancón, Ricardo and Vicente-Lidón, Raquel},
title = {HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad130}
}
EUVIMED